LH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Labcorp Holdings Inc (LH) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company's financial performance is strong, and analysts have raised price targets, the technical indicators and trading sentiment do not suggest an immediate buying opportunity. The stock is currently in a neutral to slightly bearish technical position, and hedge funds are selling. Additionally, there are no strong proprietary trading signals or recent political endorsements to support a buy decision.
The MACD is negative and expanding (-1.27), indicating bearish momentum. RSI is neutral at 31.407, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading close to its support level (S1: 276.723) with limited upside potential in the short term. The pre-market price is $275.92, below the pivot level of $282.992.
Strong financial performance in Q3 2025, with revenue up 8.58% YoY, net income up 54.22% YoY, and EPS up 55.22% YoY.
Analysts have raised price targets recently, with JPMorgan and Baird maintaining Overweight and Outperform ratings.
The stock is trading at a discount compared to its peer Quest Diagnostics, which could make it a relative safe haven in healthcare services.
Hedge funds are aggressively selling, with a 676.52% increase in selling activity over the last quarter.
CEO Adam Schechter sold shares recently, which may indicate a lack of confidence in near-term price appreciation.
MACD and RSI suggest neutral to bearish momentum, and the stock is trading near support levels, limiting immediate upside potential.
Labcorp's Q3 2025 financials show strong growth: Revenue increased by 8.58% YoY to $3.56 billion, net income rose by 54.22% YoY to $261.1 million, and EPS grew by 55.22% YoY to $3.12. Gross margin improved by 4.68% to 26.82%.
Analysts are generally positive on Labcorp, with recent price target increases from JPMorgan ($330), Baird ($326), and Piper Sandler ($300). Ratings range from Neutral to Overweight, with a consensus view of the stock as a safe haven in healthcare services.
